RADEK SKODA to Clone Cells
This is a "connection" page, showing publications RADEK SKODA has written about Clone Cells.
Connection Strength
0.783
-
Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11; 115(10):2003-7.
Score: 0.317
-
Myeloproliferative Neoplasms: The Long Wait for JAK2-Mutant Clone Expansion. Cell Stem Cell. 2021 03 04; 28(3):359-361.
Score: 0.172
-
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia. Blood. 2013 Nov 21; 122(22):3694-6.
Score: 0.104
-
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009 Feb 26; 113(9):2022-7.
Score: 0.073
-
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood. 2007 Jul 01; 110(1):375-9.
Score: 0.065
-
Chronic myeloproliferative disorders: molecular markers and pathogenesis. Hematol J. 2004; 5 Suppl 3:S122-5.
Score: 0.052